法律2026/09/25@LawDesk
Supreme Court Restores Mail Access to Mifepristone in Louisiana Case
Supreme Court of the United StatesSupreme Court of the United States, 1, 1st Street Northeast, Ward 6, Washington, District of Columbia, 20543, United States
开始于 2026/05/14已确认可信度 84%134天前The order in Nos. 25A1207 and 25A1208 is dated "[May 14, 2026]" and says "The applications for stay ... are granted".^[1]
The Supreme Court stayed the Fifth Circuit's order in Louisiana v. FDA, so mifepristone can again be prescribed by telehealth and sent by mail while the case goes on; Justices Thomas and Alito dissented.
0.77
法律2026/09/25@LawDesk
Fifth Circuit Reinstates In-Person Dispensing for Mifepristone
United States Court of Appeals for the Fifth CircuitUnited States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United States
开始于 2026/05/01已确认可信度 82%147天前The opinion in No. 26-30203 is stamped "FILED May 1, 2026" and orders that "the motion to stay the 2023 REMS under 5 U.S.C. § 705 pending appeal is GRANTED".^[1]
A Fifth Circuit panel granted Louisiana a stay of the FDA's 2023 mifepristone rules, ending telehealth prescribing and mail or pharmacy dispensing of the abortion pill nationwide until the Supreme Court stepped in.
0.73
法律2026/09/25@LawDesk
Fifth Circuit Hears Louisiana's Appeal Against Mail-Order Mifepristone
United States Court of Appeals for the Fifth CircuitUnited States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United States
开始于 2026/09/09已确认可信度 83%16天前The court's recording of 26-30203 State of Louisiana v. FDA gives "Hearing Date: Wednesday, September 9, 2026 Courtroom: En Banc Courtroom".^[1]
A Fifth Circuit panel of Judges Richman, Higginson and Douglas heard Louisiana's bid to end telehealth prescribing of mifepristone and pressed the state hard on whether it has standing to sue.
0.71
健康2026/09/25@HealthDesk
FDA Approves Evita Solutions' Generic Mifepristone
Evita SolutionsMahan Court, Federal Research Center, White Oak, Montgomery County, Maryland, 20993, United States
开始于 2025/09/30 14:20已确认可信度 83%360天前The ANDA 216616 approval letter says "the ANDA is approved, effective on the date of this letter" and is digitally signed "Date: 9/30/2025 10:20:02AM".^[1]
The FDA approved Evita Solutions' 200 mg mifepristone tablets as the second generic of the abortion pill, less than two weeks after HHS promised a safety review of the drug.
0.66
法律2026/09/24@LawDesk
联邦巡回上诉法院维持 Lululemon 在耐克健身手表专利案中的胜诉
Howard T. Markey National Courts Building, 717, Madison Place Northwest, Ward 2, Washington, District of Columbia, 20005, United StatesLululemon
开始于 2026/08/05 13:10已确认可信度 86%51天前第 2024-2134 号非判例意见书写明“裁决日期：2026 年 8 月 5 日”；案卷显示其于当天上午 09:10 录入。^[1]
联邦巡回上诉法院维持专利审判和上诉委员会的裁决：Lululemon 胜诉，耐克一项关于心率与健身手表控制台的专利中所有被质疑的权利要求均不具可专利性。
0.62
法律2026/09/24@LawDesk
联邦巡回上诉法院维持 Lululemon 胜诉，Nike 健身分享专利被判无效
Howard T. Markey National Courts Building, 717, Madison Place Northwest, Ward 2, Washington, District of Columbia, 20005, United StatesLululemon
开始于 2026/05/13 13:40已确认可信度 86%135天前编号 2024-2074 的非先例性第 36 条规则判决注明日期为“2026 年 5 月 13 日”，并盖有“Filed: 05/13/2026”（提交日期：2026 年 5 月 13 日）的印记；案卷显示该判决于当天上午 09:40 录入。^[1]
联邦巡回上诉法院以不附意见的方式维持了专利审判和上诉委员会的裁决：Lululemon 胜诉，Nike 关于将已记录的锻炼分享到社交网站的专利中受到挑战的权利要求不具可专利性。
0.61
法律2026/09/25@LawDesk
Third Circuit Lists Arm's Appeal Against Qualcomm for October 20
James A. Byrne Courthouse, 601, Market Street, Old City, Center City, Philadelphia, Philadelphia County, Pennsylvania, 19106, United StatesQualcomm
开始于 2026/10/20已排期可信度 80%25天后The clerk's letter says the case 'has been tentatively listed on the merits for Tuesday, October 20, 2026, in PHILADELPHIA, PA' and may move 'to another day within the week of October 19, 2026'.^[1]
The US Court of Appeals for the Third Circuit has listed Arm's appeal of the Delaware judgment for Qualcomm and Nuvia on the merits in Philadelphia, with oral argument at the panel's discretion.
0.61
法律2026/09/24@LawDesk
最高法院驳回皮拉尼在 Slack 直接上市案中的最后上诉
Supreme Court of the United States, 1, 1st Street Northeast, Ward 6, Washington, District of Columbia, 20543, United StatesSalesforce
开始于 2025/10/06已确认可信度 91%354天前最高法院“2025 年 10 月 6 日（周一）”的裁定清单在“调卷令申请驳回”项下列有 25-44 Pirani v. Slack Technologies, Inc.。^[1]
大法官们驳回了一名 Slack 投资者的申请，维持第九巡回上诉法院驳回其就 Slack 2019 年在纽交所直接上市提起的证券诉讼的裁定。
0.60
健康2026/09/25@HealthDesk
FDA Decision Due on Roche's Giredestrant for Early Breast Cancer
RocheMahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United States
开始于 2026/11/30已排期可信度 78%66天后Roche's^[1] release says "The FDA is expected to make a decision on the approval by 30 November 2026", the PDUFA goal date set under Priority Review.
The FDA is due to decide by 30 November 2026 whether to approve Roche's giredestrant, an oral SERD that cut the risk of recurrence or death by 30% versus standard hormone therapy in early ER-positive breast cancer.
0.58
法律2026/09/25@LawDesk
Fifth Circuit Strikes Down Nasdaq's Board Diversity Rule 9-8
United States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United StatesNasdaq
开始于 2024/12/11已确认可信度 83%1.8年前The en banc opinion in No. 21-60626 is stamped "FILED December 11, 2024" and "Date Filed: 12/11/2024".^[1]
The full US Court of Appeals for the Fifth Circuit voted 9-8 to vacate the SEC's approval of Nasdaq's rule requiring listed companies to have a woman and a minority or LGBTQ+ director on the board or explain why not.
0.58
法律2026/09/24@LawDesk
法官准许投资者对 Lululemon 的证券诉讼继续进行
40, Centre Street, Civic Center, Lower Manhattan, Manhattan, New York County, New York, 10007, United StatesLululemon
开始于 2026/03/31已确认可信度 91%178天前案卷第 58 号条目，日期为 2026 年 3 月 31 日：法官 Andrew L. Carter, Jr. 发出的“部分批准、部分驳回第 53 号撤案动议的命令”。^[1]
曼哈顿一名联邦法官部分驳回 Lululemon 撤销一宗涉及其 2023-24 年声明的股东集体诉讼的动议，并以涉嫌内幕交易为由，认定误导性陈述和主观故意的主张具有合理性。
0.58
法律2026/09/25@LawDesk
Federal Circuit Hears ParkerVision's Appeal in Qualcomm Patent Case
Howard T. Markey National Courts Building, 717, Madison Place Northwest, Ward 2, Washington, District of Columbia, 20005, United StatesQualcomm
开始于 2026/06/01 14:00已确认可信度 89%116天前The Federal Circuit's notice says 'This case has been scheduled for oral argument on June 1, 2026 at 10:00 a.m.', and the court posted the argument's audio on 1 June 2026.^[1]
A Federal Circuit panel of Judges Prost, Chen and Stark heard ParkerVision's appeal of the claim construction that ended its receiver-patent claims against Qualcomm.
0.57

The slip opinion in No. 23-235 is headed "Argued March 26, 2024—Decided June 13, 2024".^[1]

开始: 2024年6月13日可信度 90%来自来源

Supreme Court Rejects Challenge to Mifepristone in FDA v. Alliance

A unanimous Supreme Court threw out anti-abortion doctors' challenge to the FDA's rules for the abortion pill mifepristone, holding they had no standing to sue, so mail and telehealth access stayed in place.

The Supreme Court unanimously reversed the Fifth Circuit on 13 June 2024, holding that the Alliance for Hippocratic Medicine and the anti-abortion doctors with it lacked Article III standing to challenge the FDA's mifepristone rules^[1]
Justice Brett Kavanaugh wrote for the Court and Justice Clarence Thomas added a concurrence; the case was argued on 26 March 2024^[1]
The suit had begun with Judge Matthew Kacsmaryk's April 2023 order suspending the drug's 2000 approval, which the Fifth Circuit narrowed to the 2016 and later changes, including mail dispensing^[2]
The ruling left mifepristone available by telehealth and mail under the FDA's 2023 rules, but decided nothing about the merits^[2][3]
Because the Court ruled only on standing, states such as Missouri, Kansas, Idaho and later Louisiana pressed their own suits against the same rules^[3]

@LawDesk

参考资料 5可信度 84%

第一项始终是图钉的来源。总体可信度是各份资料对上方所用开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半。

[1]90%
supremecourt.gov/opinions/23pdf/23-235_n7ip.pdf
supremecourt.gov· 发布于 2026年9月25日· 开始 2024年6月13日 ✓· 占评分 38%
The slip opinion in No. 23-235 is headed "Argued March 26, 2024—Decided June 13, 2024".
[2]80%
FDA v. Alliance for Hippocratic Medicine (Wikipedia)
en.wikipedia.org· 添加于 2026年9月25日· 占评分 38%
Case history: Judge Kacsmaryk's 7 April 2023 order suspending mifepristone's approval, the Fifth Circuit's partial stay, and the unanimous 13 June 2024 ruling that the Alliance lacked standing, restoring the drug's availability under current FDA rules.^[1]
[3]80%
Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court (KFF)
kff.org· 发表于 2026年5月6日· 占评分 22%
Says the 2024 ruling held the doctors and groups lacked standing to challenge FDA's approval of mifepristone but did not reach the merits, which is why state-led suits followed.^[1]
[4]80%
Access to mifepristone remains unchanged as Supreme Court rejects abortion pill challenge (PBS NewsHour)
youtube.com· 发表于 2024年6月13日· 占评分 2%
PBS NewsHour on the day: in a unanimous decision the Court ruled anti-abortion doctors had no legal basis to challenge access to mifepristone.^[1]
[5]75%
Supreme Court rejects challenge to abortion pill mifepristone (CNN)
youtube.com· 发表于 2024年6月13日· 占评分 2%
CNN report that the ruling continues to allow the pills to be mailed to patients without an in-person doctor's visit.^[1]

建议更正

有遗漏或错误吗？用你自己的话说明：能佐证此图钉的链接、不同的开始或结束日期及理由，或缺失、有误的信息。AI 会对照此图钉的来源进行核实，搜索更好的来源，并添加任何支持你说法的页面。图钉自身的来源仍然最重要。

串

回应这个图钉

1Supreme Court Rejects Challenge to Mifepristone in FDA v. Alliance

法律2026/09/25@LawDesk
Supreme Court Restores Mail Access to Mifepristone in Louisiana Case
Supreme Court of the United StatesSupreme Court of the United States, 1, 1st Street Northeast, Ward 6, Washington, District of Columbia, 20543, United States
开始于 2026/05/14已确认可信度 84%134天前The order in Nos. 25A1207 and 25A1208 is dated "[May 14, 2026]" and says "The applications for stay ... are granted".^[1]
The Supreme Court stayed the Fifth Circuit's order in Louisiana v. FDA, so mifepristone can again be prescribed by telehealth and sent by mail while the case goes on; Justices Thomas and Alito dissented.
0.77
法律2026/09/25@LawDesk
Fifth Circuit Reinstates In-Person Dispensing for Mifepristone
United States Court of Appeals for the Fifth CircuitUnited States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United States
开始于 2026/05/01已确认可信度 82%147天前The opinion in No. 26-30203 is stamped "FILED May 1, 2026" and orders that "the motion to stay the 2023 REMS under 5 U.S.C. § 705 pending appeal is GRANTED".^[1]
A Fifth Circuit panel granted Louisiana a stay of the FDA's 2023 mifepristone rules, ending telehealth prescribing and mail or pharmacy dispensing of the abortion pill nationwide until the Supreme Court stepped in.
0.73
法律2026/09/25@LawDesk
Fifth Circuit Hears Louisiana's Appeal Against Mail-Order Mifepristone
United States Court of Appeals for the Fifth CircuitUnited States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United States
开始于 2026/09/09已确认可信度 83%16天前The court's recording of 26-30203 State of Louisiana v. FDA gives "Hearing Date: Wednesday, September 9, 2026 Courtroom: En Banc Courtroom".^[1]
A Fifth Circuit panel of Judges Richman, Higginson and Douglas heard Louisiana's bid to end telehealth prescribing of mifepristone and pressed the state hard on whether it has standing to sue.
0.71
健康2026/09/25@HealthDesk
FDA Approves Evita Solutions' Generic Mifepristone
Evita SolutionsMahan Court, Federal Research Center, White Oak, Montgomery County, Maryland, 20993, United States
开始于 2025/09/30 14:20已确认可信度 83%360天前The ANDA 216616 approval letter says "the ANDA is approved, effective on the date of this letter" and is digitally signed "Date: 9/30/2025 10:20:02AM".^[1]
The FDA approved Evita Solutions' 200 mg mifepristone tablets as the second generic of the abortion pill, less than two weeks after HHS promised a safety review of the drug.
0.66
法律2026/09/24@LawDesk
联邦巡回上诉法院维持 Lululemon 在耐克健身手表专利案中的胜诉
Howard T. Markey National Courts Building, 717, Madison Place Northwest, Ward 2, Washington, District of Columbia, 20005, United StatesLululemon
开始于 2026/08/05 13:10已确认可信度 86%51天前第 2024-2134 号非判例意见书写明“裁决日期：2026 年 8 月 5 日”；案卷显示其于当天上午 09:10 录入。^[1]
联邦巡回上诉法院维持专利审判和上诉委员会的裁决：Lululemon 胜诉，耐克一项关于心率与健身手表控制台的专利中所有被质疑的权利要求均不具可专利性。
0.62
法律2026/09/24@LawDesk
联邦巡回上诉法院维持 Lululemon 胜诉，Nike 健身分享专利被判无效
Howard T. Markey National Courts Building, 717, Madison Place Northwest, Ward 2, Washington, District of Columbia, 20005, United StatesLululemon
开始于 2026/05/13 13:40已确认可信度 86%135天前编号 2024-2074 的非先例性第 36 条规则判决注明日期为“2026 年 5 月 13 日”，并盖有“Filed: 05/13/2026”（提交日期：2026 年 5 月 13 日）的印记；案卷显示该判决于当天上午 09:40 录入。^[1]
联邦巡回上诉法院以不附意见的方式维持了专利审判和上诉委员会的裁决：Lululemon 胜诉，Nike 关于将已记录的锻炼分享到社交网站的专利中受到挑战的权利要求不具可专利性。
0.61
法律2026/09/25@LawDesk
Third Circuit Lists Arm's Appeal Against Qualcomm for October 20
James A. Byrne Courthouse, 601, Market Street, Old City, Center City, Philadelphia, Philadelphia County, Pennsylvania, 19106, United StatesQualcomm
开始于 2026/10/20已排期可信度 80%25天后The clerk's letter says the case 'has been tentatively listed on the merits for Tuesday, October 20, 2026, in PHILADELPHIA, PA' and may move 'to another day within the week of October 19, 2026'.^[1]
The US Court of Appeals for the Third Circuit has listed Arm's appeal of the Delaware judgment for Qualcomm and Nuvia on the merits in Philadelphia, with oral argument at the panel's discretion.
0.61
法律2026/09/24@LawDesk
最高法院驳回皮拉尼在 Slack 直接上市案中的最后上诉
Supreme Court of the United States, 1, 1st Street Northeast, Ward 6, Washington, District of Columbia, 20543, United StatesSalesforce
开始于 2025/10/06已确认可信度 91%354天前最高法院“2025 年 10 月 6 日（周一）”的裁定清单在“调卷令申请驳回”项下列有 25-44 Pirani v. Slack Technologies, Inc.。^[1]
大法官们驳回了一名 Slack 投资者的申请，维持第九巡回上诉法院驳回其就 Slack 2019 年在纽交所直接上市提起的证券诉讼的裁定。
0.60
健康2026/09/25@HealthDesk
FDA Decision Due on Roche's Giredestrant for Early Breast Cancer
RocheMahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United States
开始于 2026/11/30已排期可信度 78%66天后Roche's^[1] release says "The FDA is expected to make a decision on the approval by 30 November 2026", the PDUFA goal date set under Priority Review.
The FDA is due to decide by 30 November 2026 whether to approve Roche's giredestrant, an oral SERD that cut the risk of recurrence or death by 30% versus standard hormone therapy in early ER-positive breast cancer.
0.58
法律2026/09/25@LawDesk
Fifth Circuit Strikes Down Nasdaq's Board Diversity Rule 9-8
United States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United StatesNasdaq
开始于 2024/12/11已确认可信度 83%1.8年前The en banc opinion in No. 21-60626 is stamped "FILED December 11, 2024" and "Date Filed: 12/11/2024".^[1]
The full US Court of Appeals for the Fifth Circuit voted 9-8 to vacate the SEC's approval of Nasdaq's rule requiring listed companies to have a woman and a minority or LGBTQ+ director on the board or explain why not.
0.58
法律2026/09/24@LawDesk
法官准许投资者对 Lululemon 的证券诉讼继续进行
40, Centre Street, Civic Center, Lower Manhattan, Manhattan, New York County, New York, 10007, United StatesLululemon
开始于 2026/03/31已确认可信度 91%178天前案卷第 58 号条目，日期为 2026 年 3 月 31 日：法官 Andrew L. Carter, Jr. 发出的“部分批准、部分驳回第 53 号撤案动议的命令”。^[1]
曼哈顿一名联邦法官部分驳回 Lululemon 撤销一宗涉及其 2023-24 年声明的股东集体诉讼的动议，并以涉嫌内幕交易为由，认定误导性陈述和主观故意的主张具有合理性。
0.58
法律2026/09/25@LawDesk
Federal Circuit Hears ParkerVision's Appeal in Qualcomm Patent Case
Howard T. Markey National Courts Building, 717, Madison Place Northwest, Ward 2, Washington, District of Columbia, 20005, United StatesQualcomm
开始于 2026/06/01 14:00已确认可信度 89%116天前The Federal Circuit's notice says 'This case has been scheduled for oral argument on June 1, 2026 at 10:00 a.m.', and the court posted the argument's audio on 1 June 2026.^[1]
A Federal Circuit panel of Judges Prost, Chen and Stark heard ParkerVision's appeal of the claim construction that ended its receiver-patent claims against Qualcomm.
0.57

相似图钉

参考资料 5可信度 84%

建议更正

评论

串

相似图钉